Skip to main content

Bevacizumab

  • Living reference work entry
  • First Online:
Encyclopedia of Cancer
  • 146 Accesses

Definition

Avastin® made by Genentech/Roche.

Monoclonal antibody against the vascular endothelial growth factor (VEGF). Bevacizumab has activity in colorectal cancer (Colorectal Cancer Therapeutic Antibodies), non-small cell lung cancer, breast cancer, and ovarian cancer. Binding to VEGF prevents it from binding to its receptor. Originally approved by the US FDA for the treatment of colorectal cancer.

VEGF stimulates the growth of new blood vessels, a process called angiogenesis. The binding of bevacizumab is designed to inactivate VEGF so that it is no longer an effective stimulant for angiogenesis. As a result, new blood vessels are not formed. Cancers depend on the development of new blood vessels to grow. Without an adequate supply of blood, they cannot get larger and may even shrink. Bevacizumab does not work directly on the tumor, but prevents its growth by reducing its supply of blood. Bevacizumab does not cure cancer, but it can slow its growth and increase survival times. It...

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Institutional subscriptions

References

  • Jubb AM, Harris AL (2010) Biomarkers to predict the clinical efficacy of bevacizumab in cancer. Lancet Oncol 11(12):1172–1183

    Article  CAS  PubMed  Google Scholar 

See Also

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Manfred Schwab .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag Berlin Heidelberg

About this entry

Cite this entry

Schwab, M. (2014). Bevacizumab. In: Schwab, M. (eds) Encyclopedia of Cancer. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-27841-9_595-2

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-27841-9_595-2

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Online ISBN: 978-3-642-27841-9

  • eBook Packages: Springer Reference Biomedicine and Life SciencesReference Module Biomedical and Life Sciences

Publish with us

Policies and ethics